Results 71 to 80 of about 13,317 (169)

Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Acute myeloid leukemia (AML) represents 15% to 20% of all pediatric acute leukemias and is responsible for nearly 30% of deaths in this population. While high‐income countries report overall survival (OS) rates near 75%, survival in Brazil remains significantly lower, ranging between 30% and 40%.
Thais Alcantara Bonilha, Deborah Sutter Ayres Pereira, Alice Maria Boulhosa de Azevedo, Adriana Martins de Sousa, Elaine Sobral da Costa, Marcelo Gerardin Poirot Land   +5 more
wiley   +1 more source

Practices of Antifungal Prophylaxis Among Italian Pediatric Oncology–Hematology Centers

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Background IFD is a significant cause of illness and death among pediatric patients undergoing chemotherapy or HSCT. Application of AFP in children varies widely and is frequently off‐label. This survey aims to describe real‐world AFP practices across centers within AIEOP and provide an estimate of IFD incidence.
Martina Colli, Antonio Grasso, Manuela Spadea, Francesca Compagno, Lorenzo Chiusaroli, Paola Muggeo, Alessia Pancaldi, Rosamaria Mura, Daniela Onofrillo, Raffaella De Santis, Beatrice Mongelli, Angelica Barone, Simona Rinieri, Paola Coccia, Erica Ricci, Maura Faraci, Maria Rosaria D'Amico, Federica Galaverna, Pietro Gasperini, Letizia Brescia, Antonella Colombini, Riccardo Masetti, Francesco Baccelli, Simone Cesaro   +23 more
wiley   +1 more source

Effects of the HDAC6/8 Inhibitor MC1568, Alone and in Combination With Fluconazole, in Non‐Albicans Candida Species Infections

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
This study explores new antifungal strategies to combat non‐albicans Candida species. We tested clinically approved HDAC inhibitors—Vorinostat, Romidepsin, Tucidinostat—and the HDAC6/8‐selective MC1568, alone and with Fluconazole. The Fluconazole/MC1568 combination significantly enhanced antifungal activity and reduced biofilm formation.
Andrea Giammarino, Chiara Lambona, Alessia Raucci, Giovanna Simonetti, Salvatore Macrì, Angela Iuzzolino, Daniela Trisciuoglio, Sergio Valente, Gustavo Giusiano, Letizia Angiolella, Antonello Mai   +10 more
wiley   +1 more source

Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation

, 2018
Siang Fei Yeoh,1 Tae Jin Lee,2 Ka Lip Chew,3 Stephen Lin,4 Dennis Yeo,5 Sajita Setia5 1Department of Pharmacy, National University Health System, Singapore, Singapore; 2Department of Pharmacy, National University of Singapore, Singapore, Singapore ...
Yeo D, Lee TJ, Lin S, Chew KL, Yeoh SF, Setia S   +5 more
core  

Microcolony Imaging of Aspergillus fumigatus Treated with Echinocandins Reveals Both Fungistatic and Fungicidal Activities [PDF]

, 2012
Background: The echinocandins are lipopeptides that can be employed as antifungal drugs that inhibit the synthesis of 1,3-beta-glucans within the fungal cell wall.
Ingham, C.J., Schneeberger, P.M., Peter M Schneeberger, Colin J Ingham, Schneeberger Peter M., Ingham Colin J.   +5 more
core   +2 more sources

From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Recent and limited evidence indicates that oral candidiasis can disseminate Candida albicans throughout the body, leading to invasive candidiasis, such as candidemia, a life‐threatening infection. Considering antifungal resistance and global outbreaks of emergent non‐albicans Candida and related yeasts, murine models help understand dissemination ...
Julia Robledo Jerez, Marcella Vieira Ambrosio, Marcela Eduarda Olegario Fernandes, Ewerton Garcia de Oliveira Mima   +3 more
wiley   +1 more source

Potential Microbiological Effects of Higher Dosing of Echinocandins.

, 2015
The antifungal "paradoxical effect" has been described as the reversal of growth inhibition at high doses of echinocandins, most usually caspofungin.
Steinbach, W.J., Lamoth, F., Juvvadi, P.R.   +2 more
core   +1 more source

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance

, 2009
Different types of mycoses, especially invasive mycoses caused by yeasts and molds, are a growing problem in healthcare. The most notable explanation for this increase is a rise in the number of immunocompromised patients owing to advances in ...
FERA, Maria Teresa, LA CAMERA, ERMINIA, DE SARRO, Angelina   +2 more
core   +1 more source

Echinocandins and Continuous Renal Replacement Therapies: The Role of Adsorption

, 2018
The following reviews [1,2], about continuous renal replacement therapies (CRRT) and echinocandins conclude that the membranes do not significantly adsorb these antifungals. The first review [1], that evaluates several articles [3-7], concludes that the
TM Tomasa Irriguible, T m Tomasa Irriguible   +1 more
core   +1 more source

Profound cell wall remodeling in Candida parapsilosis during systemic infection confers simultaneous tolerance to echinocandins and host immunity

Microbiology Spectrum
Antifungal tolerance can promote the emergence of resistance yet often incurs fitness costs for fungal pathogens. How tolerant populations compensate for these deficits and how they may be therapeutically targeted remain poorly understood.
Farnaz Daneshnia, Liuyang Cai, Deepika Gunasekaran, Isha Gautam, Austin M. Perry, Pegah Mosharaf Ghahfarokhy, Arefeh Ebadati, Julieta Munoz, Dorian Padilla, Süleyha Hilmioglu-Polat, Shenglin Mei, Daniel J. Floyd, Miquel Àngel Schikora-Tamarit, Diego Fuentes, Maria Artigues-Lleixà, Louise A. Walker, Samuel M. Gonçalves, Mostafa Salehi, Agostinho Carvalho, Jigar V. Desai, David S. Perlin, Carol A. Munro, Alex Hopke, Tuo Wang, Toni Gabaldón, Wenjie Fang, Clarissa J. Nobile, Michael K. Mansour, Amir Arastehfar   +28 more
doaj   +1 more source